CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

被引：35
作者：
Petrioli, Roberto [1 ]
Licchetta, Antonella [1 ]
Roviello, Giandomenico [1 ]
Pascucci, Alessandra [1 ]
Francini, Edoardo [1 ]
Bargagli, Gianluca [1 ]
Conca, Raffaele [1 ]
Miano, Salvatora Tindara [1 ]
Marzocca, Giuseppe [2 ]
Francini, Guido [1 ]
机构：
[1] Univ Siena, Med Oncol Unit, I-53100 Siena, Italy
[2] Univ Siena, Dept Gen Surg, I-53100 Siena, Italy
来源：
CANCER INVESTIGATION | 2012年 / 30卷 / 01期
关键词：
Capecitabine; CEA; CA19.9; Colorectal cancer; Bevacizumab; Oxaliplatin; Tumor markers; CAPECITABINE PLUS OXALIPLATIN; PHASE-II TRIAL; CARCINOEMBRYONIC ANTIGEN; 1ST-LINE THERAPY; TUMOR-MARKERS; ADENOCARCINOMA; MULTICENTER; SURVIVAL; FOLFOX-4; STAGE;
D O I：
10.3109/07357907.2011.629380
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We evaluated the changes of the tumor markers CEA and CA19.9 as early predictors of progression in metastatic colorectal cancer (mCRC) patients participating in a clinical study and receiving chemotherapy and bevacizumab (Bev). Seventy-two patients had high baseline CEA or CA19.9 serum levels. By ROC analyses, the areas under the curves were 0.83 for variable CEA cutoff values for distinguishing progressive disease (PD) versus stable disease (SD)/partial remission (PR)/complete remission (CR), and 0.80 for variable CA19.9 cutoff values for distinguishing PD versus SD/PR/CR. Rises in CEA and CA19.9 may early signal the occurrence of progression in mCRC patients receiving chemotherapy and Bev.
引用
收藏
页码：65 / 71
页数：7
相关论文
共 50 条
  • [41] Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
    Ribero, Dario
    Wang, Huamin
    Donadon, Matteo
    Zorzi, Daria
    Thomas, Melanie B.
    Eng, Cathy
    Chang, David Z.
    Curley, Steven A.
    Abdalla, Eddie K.
    Ellis, Lee M.
    Vauthey, Jean-Nicolas
    CANCER, 2007, 110 (12) : 2761 - 2767
  • [42] Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy
    Souglakos, J.
    Kalykaki, A.
    Vamvakas, L.
    Androulakis, N.
    Kalbakis, K.
    Agelaki, S.
    Vardakis, N.
    Tzardi, M.
    Kotsakis, A. P.
    Gioulbasanis, J.
    Tsetis, D.
    Sfakiotaki, G.
    Chatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 305 - 310
  • [43] Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings
    Kubicka, S.
    Greil, R.
    Andre, T.
    Bennouna, J.
    Sastre, J.
    Van Cutsem, E.
    von Moos, R.
    Oesterlund, P.
    Reyes-Rivera, I.
    Mueller, T.
    Makrutzki, M.
    Arnold, D.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2342 - 2349
  • [44] Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer
    Diaz, Roberto
    Aparicio, Jorge
    Molina, Jorge
    Palomar, Laura
    Gimenez, Alejandra
    Ponce, Jose
    Segura, Angel
    Gomez-Codina, Jose
    MEDICAL ONCOLOGY, 2006, 23 (03) : 347 - 357
  • [45] Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
    Kjersem, J. B.
    Ikdahl, T.
    Lingjaerde, O. C.
    Guren, T.
    Tveit, K. M.
    Kure, E. H.
    MOLECULAR ONCOLOGY, 2014, 8 (01) : 59 - 67
  • [46] Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
    Imai, Hiroo
    Saijo, Ken
    Komine, Keigo
    Yoshida, Yuya
    Sasaki, Keiju
    Suzuki, Asako
    Ouchi, Kota
    Takahashi, Masahiro
    Takahashi, Shin
    Shirota, Hidekazu
    Takahashi, Masanobu
    Ishioka, Chikashi
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [47] Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
    Nixon, Andrew B.
    Sibley, Alexander B.
    Liu, Yingmiao
    Hatch, Ace J.
    Jiang, Chen
    Mulkey, Flora
    Starr, Mark D.
    Brady, John C.
    Niedzwiecki, Donna
    Venook, Alan P.
    Baez-Diaz, Luis
    Lenz, Heinz-Josef
    O'Neil, Bert H.
    Innocenti, Federico
    Meyerhardt, Jeffrey A.
    O'Reilly, Eileen M.
    Owzar, Kouros
    Hurwitz, Herbert, I
    CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2779 - 2788
  • [48] Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy
    Huang, Ching-Wen
    Ma, Cheng-Jen
    Su, Wei-Chih
    Chen, Yi-Ting
    Tsai, Hsiang-Lin
    Yeh, Yung-Sung
    Chang, Tsung-Kun
    Hsu, Wen-Hung
    Yu, Fang-Jung
    Wang, Jaw-Yuan
    ONCOLOGY RESEARCH, 2020, 28 (7-8) : 701 - 714
  • [49] ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt
    Kassem, Amira B.
    Salem, Salem Eid
    Abdelrahim, Mohamed E.
    Said, Amira S. A.
    Salahuddin, Ahmad
    Hussein, Marwa Mahmoud
    Bahnassy, Abeer A.
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2017, 102 (01) : 78 - 85
  • [50] Comparing Time to Disease Progression of Irinotecan and Oxaliplatin-based Chemotherapies in Colorectal Cancer Patients With Liver Only Metastasis
    Varol, Umut
    Karaca, Burcak
    Cakar, Burcu
    Sezgin, Canfeza
    Karabulut, Bulent
    Uslu, Ruchan
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (04): : 388 - 391
12345